Sarepta shares surge on muscular dystrophy drug filing
May 19, 2015 at 17:46 PM EDT
Sarepta Therapeutics Inc. says late Tuesday it plans to begin the process of getting regulatory approval for its treatment of a rare genetic disorder, following a meeting with the U.S. Food and Drug Administration.
